Self-organizing synthetic human lungs on microchips to fight infection by RSV
Ended Project Grant Awarded Last action
- Award ID
- R43AI174385
- Recipient
-
Rumi Scientific, Inc. UEI Y1U1A5Y75CN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- New York, NY 10065, USA
Award details come from USAspending.gov.
Description
- Abstract
- RSV is a major global threat that accounts for a significant share of respiratory disease and mortality among patients at risk. Infection by highly pathogenic RSV results in acute lung injury, lrti, and pneumonia-associated complications. As treatments for RSV are very limited in use and efficacy, the development of physiological models of this disease is key to develop therapeutics that limit infection by this virus and associated pathology. This proposal will capitalize on rumiviro's mini-lung platform that offers inexhaustible access to genetically matched organotypic human lung tissue to model infection by respiratory viruses. This platform will be deployed to model RSV infection in physiological lung tissue and identify therapeutics for this disease at scale. We will first screen a collection of 23,000 compounds of a highly diverse phenotypic library of bioactive compounds for their ability to mitigate infection by RSV. HIT candidates will be further validated for their ability to inhibit multiple clinical strains of RSV in mini- lungs and primary lung tissue EX vivo. This work will have transformative influence for the subsequent development of therapeutics and will enable further validation of therapeutic candidates based on drug metabolism, pharmacokinetic analysis, in vivo proof-of-concept and lead optimization efforts in follow-up phase 2 studies. This work will provide a highly efficient framework for the identification and development of RSV therapeutics with the promise of finding anti-infective therapeutics that mitigate the RSV-induced pathology in patients at risk.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R43AI174385?
R43AI174385 was awarded to Rumi Scientific, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 22, 2023.
How much is award R43AI174385 worth?
$300,000 has been obligated on R43AI174385.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award